William Blair & Company
NGNE icon

William Blair & Company’s Neurogene NGNE Stock Holding History

William Blair & Company’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Sell
146,905
-21,313
-13% -$587K 0.01% 545
2026
Q1 		$3.39M Buy
168,218
+4,563
+3% +$88.4K 0.01% 596
2025
Q4 		$3.37M Buy
163,655
+21,835
+15% +$544K 0.01% 609
2025
Q3 		$2.46M Buy
141,820
+8,584
+6% +$172K 0.01% 681
2025
Q2 		$1.99M Sell
133,236
-17,944
-12% -$282K 0.01% 716
2025
Q1 		$1.77M Buy
151,180
+88,540
+141% +$1.54M 0.01% 743
2024
Q4 		$1.43M Buy
+62,640
New +$2.33M ﹤0.01% 798

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

William Blair & Company's NGNE Position: Q2 2026 in Review

William Blair & Company reduced its Neurogene (NGNE) stake by 13% in Q2 2026, selling an estimated $587K and leaving 146,905 shares worth $4.62M. The position accounts for 0.01% of the portfolio, ranked #545.

William Blair & Company first reported a position in NGNE in Q4 2024 and has held it in 7 quarters since. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • William Blair & Company held 146,905 shares of Neurogene worth $4.62M as of Q2 2026.
  • William Blair & Company sold 21,313 Neurogene shares in Q2 2026, an estimated $587K.
  • Neurogene made up 0.01% of William Blair & Company's portfolio in Q2 2026, its #545 holding.
  • William Blair & Company first reported a position in Neurogene in Q4 2024 and has held it in 7 quarters since.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.